# AI strain-design & engineering platforms AI-native software platforms that design microbial strains, proteins and antibodies computationally — generative models, protein language models and closed-loop automated labs — distinct from the traditional wet-lab strain-engineering CRO service model. Source: https://en.bioecon.ru/technology/ai-strain-design-engineering-platforms/ Updated: 2026-08-18 ## Overview and value chain Markers: [EC: AI-native protein/strain design & autonomous lab platforms | OECD: Bioeconomy policy & governance | Regulator: none dedicated] AI strain-design and engineering platforms are a B2B services category providing AI-native software that designs microbial strains, proteins and antibodies computationally, distinct from the traditional wet-lab strain-engineering contract-research-organization model. Ginkgo Bioworks launched Ginkgo Cloud Lab in 2026, a browser-based interface letting researchers run biological protocols on its autonomous lab infrastructure directly, transitioning benchwork to cloud-accessible automation. Absci runs Origin-1, a generative AI platform for de novo antibody design against novel epitopes, and collaborated with Twist Bioscience to combine its generative-AI drug-creation platform with DNA synthesis to accelerate novel therapeutic antibody design. Cradle runs an AI protein-design platform, with its CRADLE-1 model performing automated lead optimization of proteins as a next step beyond de novo generation. LabGenius operates a closed-loop discovery platform built around its EVA platform, unlocking high-performing molecules with non-intuitive designs across binder, linker and half-life-extension-domain building blocks. EvolutionaryScale develops the ESM (Evolutionary Scale Modeling) family of protein language models, open-sourced and widely adopted, with thousands of GitHub stars reflecting broad developer and research uptake. The key directions of AI strain-design and engineering platforms are: 1. **Generative protein design models:** AI models that generate novel protein and antibody structures de novo against specified targets or epitopes, rather than screening natural variants. 2. **Autonomous lab infrastructure:** cloud-accessible robotic lab infrastructure letting researchers run biological protocols remotely through a software interface. 3. **Closed-loop design-build-test-learn platforms:** integrated platforms where AI-generated designs are automatically built, tested and the results fed back to improve the next design cycle. 4. **Protein language models:** large-scale models trained on protein sequence/structure data, providing a foundational layer for downstream generative design and lead-optimization tools. ### Sectoral value chain ``` [Target/epitope specification] ──> [AI-generated candidate design] ──> [Automated build/synthesis] │ (Closed-loop testing) │ [Lead candidate selection] <──── [Data feedback to model] <─── [Functional/binding assay] ``` ### Value chain levels | Level | Description | Key inputs/outputs | |:---|:---|:---| | **Target/epitope specification** | Defining the target protein, epitope or functional specification the AI design process must satisfy. | **In:** Research/therapeutic objective.
**Out:** Target specification. | | **AI-generated candidate design** | Generative or protein-language models produce novel candidate protein, antibody or strain designs against the specification. | **In:** Target specification.
**Out:** Candidate design set. | | **Automated build/synthesis** | Candidate designs are synthesized or constructed, often via automated or robotic lab infrastructure. | **In:** Candidate design set.
**Out:** Physical candidate constructs. | | **Functional/binding assay** | Physical candidates are tested for the target function or binding property in automated assays. | **In:** Physical candidate constructs.
**Out:** Assay results. | | **Data feedback to model** | Assay results are fed back into the AI model to improve subsequent design rounds. | **In:** Assay results.
**Out:** Updated model/training data. | | **Lead candidate selection** | The best-performing candidates from the closed-loop cycle are selected as leads for further development. | **In:** Updated model/training data, assay results.
**Out:** Selected lead candidates. | Cross-cutting technologies of the sector: - **Generative protein design models:** AI models generating novel protein and antibody structures de novo against a specified target or epitope. - **Autonomous lab infrastructure:** cloud-accessible robotic lab infrastructure letting researchers run biological protocols remotely through a software interface. - **Closed-loop design-build-test-learn:** integrated platforms where AI-generated designs are automatically built, tested and the results fed back to improve subsequent design cycles. --- ## US The United States hosts the leading AI-native strain, protein and antibody design platforms, spanning cloud lab infrastructure, generative drug design and open-source protein language models. ### Ginkgo Bioworks' Cloud Lab, Absci's Origin-1 antibody design, EvolutionaryScale's ESM models - **Ginkgo Bioworks:** launched Ginkgo Cloud Lab in 2026, a browser-based interface letting researchers run biological protocols on its autonomous lab infrastructure directly, transitioning benchwork to cloud-accessible automation. - **Absci:** runs Origin-1, a generative AI platform for de novo antibody design against novel epitopes, and collaborated with Twist Bioscience to combine generative-AI drug creation with DNA synthesis. - **EvolutionaryScale:** develops the ESM (Evolutionary Scale Modeling) family of protein language models, open-sourced and widely adopted across the research community. --- ## CN China is covered qualitatively rather than through a live-screened Chinese vendor: candidate Chinese AI strain-design platforms searched during this screen returned no confirming 2026 source specific to this service category. ### No China-headquartered vendor confirmed in this screen - **Search outcome:** two candidate Chinese firms were searched during this screen and neither returned a confirming live 2026 source for this specific service category. - **Market presence:** China has substantial synthetic-biology R&D investment, but no China-headquartered AI-native strain/protein-design platform vendor was independently confirmed in this screen. --- ## EU Europe hosts specialist AI protein-engineering platforms in the Netherlands and UK, applying generative and closed-loop design methods to lead optimization and novel molecule design. ### Cradle's automated lead optimization, LabGenius' closed-loop discovery platform - **Cradle:** headquartered in the Netherlands, runs an AI protein-design platform, with its CRADLE-1 model performing automated lead optimization of proteins as a next step beyond de novo generation. - **LabGenius:** headquartered in the UK, operates a closed-loop discovery platform built around its EVA platform, unlocking high-performing molecules with non-intuitive designs. --- ## Leading companies and research institutes | Company / Institute | Country | Key products / platforms | Tech features | Status 2026 | |:---|:---|:---|:---|:---| | **Ginkgo Bioworks** | 🇺🇸 USA | Ginkgo Cloud Lab | Browser-based autonomous lab access | commercial | | **Absci** | 🇺🇸 USA | Origin-1 generative antibody design | De novo design against novel epitopes | commercial | | **Cradle** | 🇳🇱 Netherlands | CRADLE-1 protein design | Automated lead optimization | commercial | | **LabGenius** | 🇬🇧 UK | EVA closed-loop discovery platform | Non-intuitive high-performing designs | commercial | | **EvolutionaryScale** | 🇺🇸 USA | ESM protein language models | Open-source, broad developer adoption | commercial | --- ## Tech stack and innovations The AI strain-design and engineering platform technology stack combines generative modeling, protein language models and closed-loop automation to compress design cycles: 1. **Generative de novo protein/antibody design:** - Absci's Origin-1 generates novel antibody candidates de novo against specified novel epitopes, moving beyond screening natural antibody libraries. 2. **Automated lead optimization beyond de novo generation:** - Cradle's CRADLE-1 model performs automated lead optimization as a distinct next step after de novo protein generation, refining candidates toward manufacturability and performance. 3. **Cloud-accessible autonomous lab infrastructure:** - Ginkgo Bioworks' Cloud Lab lets researchers transition benchwork directly to autonomous lab infrastructure through a browser interface, removing physical-lab-access as a bottleneck. --- ## Value chains and production pipelines ### Industrial pipeline for an AI-driven protein/strain design cycle ``` ┌───────────────────────────┐ ┌───────────────────────────┐ │ 1. Target/epitope │ ───> │ 2. AI-generated │ │ specification │ │ candidate design │ └───────────────────────────┘ └───────────────────────────┘ │ ▼ ┌───────────────────────────┐ ┌───────────────────────────┐ │ 4. Functional/binding │ <─── │ 3. Automated │ │ assay │ │ build/synthesis │ └───────────────────────────┘ └───────────────────────────┘ │ ▼ ┌───────────────────────────┐ ┌───────────────────────────┐ │ 5. Data feedback │ ───> │ 6. Lead candidate │ │ to model │ │ selection │ └───────────────────────────┘ └───────────────────────────┘ ``` #### Stage 1: Target/epitope specification The target protein, epitope or functional specification the AI design process must satisfy is defined. #### Stage 2: AI-generated candidate design Generative or protein-language models produce novel candidate protein, antibody or strain designs against the specification. #### Stage 3: Automated build/synthesis Candidate designs are synthesized or constructed, often via automated or robotic lab infrastructure. #### Stage 4: Functional/binding assay Physical candidates are tested for the target function or binding property in automated assays. #### Stage 5: Data feedback to model Assay results are fed back into the AI model to improve subsequent design rounds. #### Stage 6: Lead candidate selection The best-performing candidates from the closed-loop cycle are selected as leads for further development.